4.4 Article

Accuracy of Continuous Glucose Monitoring During Exercise in Type 1 Diabetes Pregnancy

期刊

DIABETES TECHNOLOGY & THERAPEUTICS
卷 15, 期 3, 页码 223-229

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2012.0292

关键词

-

资金

  1. Diabetes UK [BDA 07/003551]
  2. Juvenile Diabetes Research Foundation
  3. Abbott Diabetes Care (Freestyle Navigator CGM and sensors)
  4. Investigator-Initiated Study Program of Animas Corporation (Animas 2020(R) insulin pump)
  5. Medical Research Council Centre for Obesity and Related Metabolic Diseases
  6. National Institute for Health Research Cambridge Biomedical Research Centre
  7. Addenbrooke's Clinical Research Facility (Cambridge, United Kingdom)
  8. Medtronic
  9. Roche
  10. Novo Nordisk
  11. Eli Lilly
  12. Becton Dickinson
  13. MRC [G0600717] Funding Source: UKRI
  14. Diabetes UK [07/0003551] Funding Source: researchfish
  15. Medical Research Council [G0600717, G0600717B] Funding Source: researchfish
  16. National Institute for Health Research [CDF-2013-06-035, PDF/01/036] Funding Source: researchfish

向作者/读者索取更多资源

Background: Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. Subjects and Methods: As part of a study of 24-h closed-loop insulin delivery in 12 women with T1D (disease duration, 17.6 years; glycosylated hemoglobin, 6.4%) during pregnancy (gestation, 21 weeks), we evaluated the Freestyle Navigator (R) sensor (Abbott Diabetes Care, Alameda, CA) during afternoon (15:00-18:00 h) and morning (09:30-12:30 h) exercise (55 min of brisk walking on a treadmill followed by a 2-h recovery), compared with sedentary conditions (18:00-09:00 h). Plasma (reference) glucose, measured at regular 15-30-min intervals with the YSI Ltd. (Fleet, United Kingdom) model YSI 2300 analyzer, was used to assess CGM performance. Results: Sensor accuracy, as indicated by the larger relative absolute difference (RAD) between paired sensor and reference glucose values, was lower during exercise compared with rest (median RAD, 11.8% vs. 18.4%; P < 0.001). These differences remained significant when correcting for plasma glucose relative rate of change (P < 0.001). Analysis by glucose range showed lower accuracy during hypoglycemia for both sedentary (median RAD, 24.4%) and exercise (median RAD, 32.1%) conditions. Using Clarke error grid analysis, 96% of CGM values were clinically safe under resting conditions compared with only 87% during exercise. Conclusions: Compared with sedentary conditions, accuracy of the Freestyle Navigator CGM was lower during moderate-intensity exercise in pregnant women with T1D. This difference was particularly marked in hypoglycemia and could not be solely explained by the glucose rate of change associated with physical activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Endocrinology & Metabolism

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Moshe Phillip, Revital Nimri, Richard M. Bergenstal, Katharine Barnard-Kelly, Thomas Danne, Roman Hovorka, Boris P. Kovatchev, Laurel H. Messer, Christopher G. Parkin, Louise Ambler-Osborn, Stephanie A. Amiel, Lia Bally, Roy W. Beck, Sarah Biester, Torben Biester, Julia E. Blanchette, Emanuele Bosi, Charlotte K. Boughton, Marc D. Breton, Sue A. Brown, Bruce A. Buckingham, Albert Cai, Anders L. Carlson, Jessica R. Castle, Pratik Choudhary, Kelly L. Close, Claudio Cobelli, Amy B. Criego, Elizabeth Davis, Carine de Beaufort, Martin de Bock, Daniel J. DeSalvo, J. Hans DeVries, Klemen Dovc, Francis J. Doyle, Laya Ekhlaspour, Naama Fisch Shvalb, Gregory P. Forlenza, Geraldine Gallen, Satish K. Garg, Dana C. Gershenoff, Linda A. Gonder-Frederick, Ahmad Haidar, Sara Hartnell, Lutz Heinemann, Simon Heller, Irl B. Hirsch, Korey K. Hood, Diana Isaacs, David C. Klonoff, Olga Kordonouri, Aaron Kowalski, Lori Laffel, Julia Lawton, Rayhan A. Lal, Lalantha Leelarathna, David M. Maahs, Helen R. Murphy, Kirsten Norgaard, David O'Neal, Sean Oser, Tamara Oser, Eric Renard, Michael C. Riddell, David Rodbard, Steven J. Russell, Desmond A. Schatz, Viral N. Shah, Jennifer L. Sherr, Gregg D. Simonson, R. Paul Wadwa, Candice Ward, Stuart A. Weinzimer, Emma G. Wilmot, Tadej Battelino

Summary: The global prevalence of diabetes continues to be a challenge and the advances in automated insulin delivery (AID) technologies have shown to be safe and effective in helping patients achieve their glycemic goals. However, there is a lack of guidance for clinicians on using AID systems in clinical settings.

ENDOCRINE REVIEWS (2023)

Article Endocrinology & Metabolism

Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery

Hood Thabit, Womba Mubita, Jose Rubio, Mini Karuppan, Jonathan Schofield, Malgorzata E. Willinska, Roman Hovorka, Lalantha Leelarathna

DIABETES OBESITY & METABOLISM (2023)

Letter Endocrinology & Metabolism

Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes

Hood Thabit, Charlotte Boughton, Womba Mubita, Jose Rubio, Julia K. Mader, Parth Narendran, Mark Evans, Lalantha Leelarathna, Malgorzata E. Wilinska, Catherine Fullwood, Alice M. Gregory, Roman Hovorka, Martin K. Rutter

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery

Gabija Krutkyte, Jonathan Roos, Daniel Schuerch, Cecilia Czerlau, Malgorzata E. Wilinska, Patrick Y. Wuethrich, David Herzig, Roman Hovorka, Andreas P. Vogt, Beat Gloor, Lia Bally

Summary: This study evaluated the perioperative glucose management in patients undergoing pancreatic surgery. The use of the fully closed-loop insulin therapy resulted in better glucose control without increasing the risk of hypoglycemia.

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Endocrinology & Metabolism

Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes: Healthcare Professionals' Views About Potential Challenges and Solutions

David Rankin, Ruth I. Hart, Barbara Kimbell, Katharine Barnard-Kelly, Anna Brackenridge, Caroline Byrne, Corinne Collett, Anna R. Dover, Sara Hartnell, Katharine F. Hunt, Tara T. M. Lee, Robert S. Lindsay, David R. McCance, Alastair McKelvey, Gerry Rayman, Rebecca M. Reynolds, Eleanor M. Scott, Sara L. White, Roman Hovorka, Helen R. Murphy, Julia Lawton, iDAPT Collaborative Grp

Summary: This study aimed to explore healthcare professionals' views on the training and support needed to roll out closed-loop technology to pregnant women with type 1 diabetes. Interviews with 19 healthcare professionals were conducted, and an online workshop involving 15 trial team members was used to gather recommendations. The results revealed that healthcare professionals were optimistic about a national rollout of closed-loop, but they also anticipated various challenges.

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Endocrinology & Metabolism

Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study

Julia Ware, Janet M. Allen, Charlotte K. Boughton, Alina Cezar, Sara Hartnell, Malgorzata E. Wilinska, Ajay Thankamony, Mark Deakin, Hannah Leyland, Karen Phelan, Keith Thornborough, Roman Hovorka

Summary: This study evaluated the use of hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp) in very young children with type 1 diabetes (T1D). The results showed that there was no significant difference in glycemic control between HCL with Fiasp and standard insulin aspart (IAsp) in children aged 2-6 years with T1D.

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Letter Endocrinology & Metabolism

Variability of Insulin Requirements in Adults with Type 2 Diabetes During Fully Closed-Loop Insulin Delivery

Rama Lakshman, Aideen B. Daly, Munachiso Nwokolo, Sara Hartnell, Malgorzata E. Wilinska, Alina Cezar, Mark L. Evans, Roman Hovorka, Charlotte K. Boughton

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Endocrinology & Metabolism

Time Spent in Hypoglycemia According to Age and Time of Day: Observations During Closed-Loop Insulin Delivery

Heba Alwan, Julia Ware, Charlotte E. Boughton, Malgorzata M. Wilinska, Janet Allen, Rama Lakshman, Munachiso Nwokolo, Sara Hartnell, Lia Bally, Carine de Beaufort, Rachel E. J. Besser, Fiona M. Campbell, Nikki Davis, Louise Denvir, Mark L. Evans, Elke Froehlich-Reiterer, Atrayee Ghatak, Sabine E. Hofer, Thomas M. Kapellen, Lalantha Leelarathna, Julia K. Mader, Parth Narendran, Birgit Rami-Mehrar, Martin Tauschmann, Hood Thabit, Ajay Thankamony, Roman Hovorka

Summary: This study aimed to assess the difference in percentage of time spent in hypoglycemia during closed-loop insulin delivery among different age groups and time of day. The results showed that the median time spent in hypoglycemia over the 24-hour period was highest in children and adolescents, followed by very young children, adults, and older adults. Time spent in hypoglycemia during nighttime was lower than during daytime across all age groups.

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Endocrinology & Metabolism

Implementation of fully closed-loop insulin delivery for inpatients with diabetes: Real-world outcomes

Charlotte K. Boughton, Sara Hartnell, Nicola Hobday, Andrea Lake, Katy Davenport, Aideen Daly, Candice Ward, Caroline Taylor, Roman Hovorka, Vishakha Bansiya

Summary: The study investigated the feasibility of implementing a fully closed-loop insulin delivery system in a hospital setting and found that it can be safely and effectively implemented in complex medical and surgical inpatients with challenging glycaemic control.

DIABETIC MEDICINE (2023)

Article Endocrinology & Metabolism

Healthcare professionals' views about how pregnant women can benefit from using a closed-loop system: Qualitative study

Julia Lawton, David Rankin, Sara Hartnell, Tara Lee, Anna R. Dover, Rebecca M. Reynolds, Roman Hovorka, Helen R. Murphy, Ruth I. Hart, AiDAPT Collaborative Grp

Summary: This study explored the benefits of using the CamAPS FX system during the AiDAPT trial for pregnant women with type 1 diabetes. Healthcare professionals highlighted the clinical and quality-of-life benefits, but emphasized the importance of effective collaboration between healthcare professionals, pregnant women, and the closed-loop system. They recommended offering closed-loop systems to all pregnant women with type 1 diabetes in the future.

DIABETIC MEDICINE (2023)

Article Endocrinology & Metabolism

Sleep Quality and Quantity in Caregivers of Children with Type 1 Diabetes Using Closed-Loop Insulin Delivery or a Sensor-Augmented Pump

Juan J. Madrid-Valero, Julia Ware, Janet M. Allen, Charlotte K. Boughton, Sara Hartnell, Malgorzata E. Wilinska, Ajay Thankamony, Carine de Beaufort, Ulrike Schierloh, Fiona M. Campbell, Judy Sibayan, Laura E. Bocchino, Craig Kollman, Roman Hovorka, Alice M. Gregory, KidsAP Consortium

Summary: This study compared sleep quality and quantity in caregivers of children using a closed-loop system (CL) or sensor-augmented pump (SAP) therapy. The results showed that parents in the CL group reported shorter sleep duration but better sleep quality, fewer awakenings, and less wake after sleep onset compared to the SAP group.

PEDIATRIC DIABETES (2023)

Article Medicine, General & Internal

Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial-study protocol

Benjamin Davies, Oliver D. Mowforth, Stefan Yordanov, Daniel Alvarez-Berdugo, Simon Bond, Marianna Nodale, Paula Kareclas, Lynne Whitehead, Jon Bishop, Siddharthan Chandran, Sarah Lamb, Mark Bacon, Marios C. Papadopoulos, Michelle Starkey, Iwan Sadler, Lara Smith, Sukhvinder Kalsi-Ryan, Adrian Carpenter, Rikin A. Trivedi, Martin Wilby, David Choi, Ian B. Wilkinson, Michael G. Fehlings, Peter John Hutchinson, Mark R. N. Kotter

Summary: This study aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in Degenerative cervical myelopathy (DCM). It is a multicentre, double-blind, randomised, placebo-controlled trial. The primary endpoints are pain and physical function measured at 6 months after surgery.

BMJ OPEN (2023)

Letter Endocrinology & Metabolism

Closed-Loop from Diagnosis of Type 1 Diabetes in Children and Young People

Atrayee K. Ghatak, Charlotte M. Boughton, Janet Allen, Julia E. Ware, Malgorzata Wilinska, Sara Hartnell, Ajay Thankamony, Tabitha Randell, Rachel E. J. Besser, Daniela Elleri, Nicola M. Trevelyan, Fiona Campbell, Roman Hovorka, CLOuD Consortium

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Article Endocrinology & Metabolism

Real-World Evidence Analysis of a Hybrid Closed-Loop System

Heba Alwan, Malgorzata E. Wilinska, Yue Ruan, Julien Da Silva, Roman Hovorka

Summary: We analyzed real-world evidence to assess the performance of the mylife CamAPS FX hybrid closed-loop system. Users from 15 countries across different age groups who used the system between May 9, 2022, and December 3, 2022, were included in the analysis (N = 1805). The results showed that glycemic outcomes from this real-world evidence are comparable to previous randomized controlled studies, confirming the efficacy of this hybrid closed-loop system in real-world settings.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2023)

Article Rheumatology

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Rona M. Smith, Rachel B. Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L. Rhee, Robert Spiera, Antoine G. Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A. Merkel

Summary: Following remission induction with rituximab, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse.

ANNALS OF THE RHEUMATIC DISEASES (2023)

暂无数据